United States· US:70842-140_4c7649f3-4d38-47e2-aa0d-2ed606bb930a
Orbactiv
A oritavancin product containing oritavancin, registered in United States by Melinta Therapeutics, LLC. The same ATC class is registered in 12 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Oritavancin is registered in 12 of 19 countries.
Countries holding a registration under ATC J01XA05 (oritavancin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Oritavancin · ATC J01XA05
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ORITAVANCIN
- Manufacturer
- Melinta Therapeutics, LLC
- Country
- United States (US)
- ATC code
- J01XA05
- ATC class
- Oritavancin
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 20, 2026
Packs & prices · 2
- ndc1170842140033 VIAL, GLASS in 1 CARTON (70842-140-03) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS (70842-140-01)
- ndc1170842-140-03
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
68 interactions on record for oritavancin.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Oritavancin · interactions on record
68 records
- 2 severe
- 64 moderate
- 2 minor
Most severe, free to view
- HeparinB01AB01severe
- HeparinB05CX05severe
- Sodium picosulfateA06AB08moderate
- NitisinoneA16AX04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Oritavancin in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTenkasi 1200 mgMenarini International Operations Luxembourg
- SwitzerlandTenkasi 1200 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungA. Menarini GmbH
- CzechiaTENKASIMenarini International Operations Luxembourg S.A., Luxembourg
- SpainTENKASI 1200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMenarini International Operations Luxembourg S.A.
- FranceTENKASI 1200 mg, poudre pour solution à diluer pour perfusionMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG
- PolandTenkasiMenarini International Operations Luxembourg S.A.
- IrelandTenkasi 1200 mg powder for concentrate for solution for infusionMenarini International Operations Luxembourg S.A.
- NetherlandsTenkasi 1200 mg poeder voor concentraat voor oplossing voor infusieMenarini International Operations Luxembourg S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tenkasi
- Liechtenstein · Tenkasi
- Norway · Tenkasi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/31619e90-f810-4c84-a34a-04d170f2755b GET /v1/drugs/31619e90-f810-4c84-a34a-04d170f2755b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "400",
"substance": "ORITAVANCIN",
"productndc": "70842-140",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA206334",
"marketing_category": "NDA"
}See everything about oritavancin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.